

Introducing BREZTRI AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate)
A new treatment for moderate, severe or very severe COPD*¹

 **Date:**

 **Time:**

 **Venue:**

Speakers:

Agenda:

TIME	TOPIC	SPEAKER

To register for the face to face meeting, please scan:



or

[Click Here](#)

To register for the virtual meeting, please scan:



or

[Click Here](#)

For any questions regarding the meeting, please contact



*BREZTRI AEROSPHERE® is indicated as maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) who require treatment with a combination of an inhaled corticosteroid (ICS), a long-acting β_2 -agonist (LABA), and a long-acting muscarinic antagonist (LAMA). BREZTRI is not indicated for the initiation of therapy in COPD.¹



BREZTRI
AEROSPHERE®

(budesonide, glycopyrronium, and
formoterol fumarate) Inhalation Aerosol

PBS Information: Authority required (STREAMLINED) for the treatment of COPD.
Refer to PBS Schedule for full authority information.

BEFORE PRESCRIBING PLEASE REVIEW FULL PRODUCT INFORMATION AVAILABLE
ON REQUEST FROM ASTRAZENECA ON 1800 805 342 OR www.astrazeneca.com.au/PI

BREZTRIAEROSPHERE® (budesonide 160µg/ glycopyrronium 7.2µg/ formoterol (eformoterol) fumarate dihydrate 5µg) pressurised metered dose inhaler for oral inhalation. Therapeutic indications: Maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) who require treatment with a combination of an inhaled corticosteroid (ICS), a long-acting β_2 -agonist (LABA), and a long-acting muscarinic antagonist (LAMA). BREZTRI is not indicated for the initiation of therapy in COPD. **Dosage:** Adults \geq 18 years: 2 actuations twice daily. **Contraindications:** Hypersensitivity to any of the ingredients. **Special Warning and Precautions: Not indicated** for the treatment of asthma, or for the treatment of acute episodes of bronchospasm, or as rescue therapy to treat an acute COPD exacerbation; patients transferring from oral corticosteroids (OCS) may remain at risk of impaired adrenal function - additional systemic corticosteroid cover should be considered during periods of stress or elective surgery; discontinue BREZTRI immediately should paradoxical bronchospasm occur (as with other inhaled medicines, bronchospasm may be life-threatening); not for use with other medicines containing a LABA or LAMA; caution in patients with clinically significant cardiovascular disease, thyrotoxicosis or prolonged QTc interval; possible systemic effects of ICS (see full PI); consider referral to an ophthalmologist in patients who develop ocular symptoms or use BREZTRI long term; hypokalaemia; hyperglycaemia; caution in patients with symptomatic prostatic hyperplasia, urinary retention or narrow-angle glaucoma; an increase in the incidence of pneumonia, including requiring hospitalisation, has been observed in patients with COPD receiving inhaled corticosteroids - physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections can overlap with symptoms of COPD; oropharyngeal candidiasis; severely impaired renal or hepatic function – monitor closely and use only if benefit outweighs risk; BREZTRI should only be used during pregnancy if the expected benefits outweigh the potential risks (category B3); lactation - use only if the expected benefit to the mother outweigh potential risk to the child; no relevant use in children <18 years in COPD. See full PI for further information. **Interactions:** Not for use with other LABA and/or LAMA containing medicines; strong CYP3A4 inhibitors, e.g. itraconazole, ketoconazole, HIV protease inhibitors, cobicistat containing products; beta-receptor blockers; medicines known to prolong QTc interval, e.g. MAOIs, tricyclic antidepressants; if hypokalaemic, drugs that may potentiate hypokalaemia, e.g. non-potassium sparing diuretics; other antimuscarinics and sympathomimetics. **Adverse effects:** *Very common* (\geq 10%): nasopharyngitis. *Common* (\geq 1%): COPD, upper respiratory tract infection, pneumonia, bronchitis, back pain, hypertension, dyspnoea, headache, urinary tract infection, influenza, sinusitis, muscle spasm, cough, oral candidiasis, diarrhoea, hyperglycaemia, anxiety, insomnia, palpitations, dysphonia, nausea; others, see full PI. **Date of first approval:** 19 July 2021.

Reference: 1. BREZTRI AEROSPHERE® Approved Product Information.

HEALTH & SAFETY: AstraZeneca values your health and safety. We choose to use venues and suppliers who have COVID-Safe plans in place. Venues may require you to register on arrival for contact tracing reasons or to show current vaccination status, and adherence to other COVID safe measures. All local regulations and laws around social distancing, vaccination status, and attendee numbers must be adhered to by all attendees. Please ensure that you have registered, as we may not be able to accommodate you if we have reached these limits. There will be access to hand sanitiser, tissues and face masks should you need/wish to use these. If you are unwell, tested positive for, or had any known symptoms, of COVID-19 in the last 14 days, please ensure you stay home.

Attendance at AstraZeneca educational meetings is by invitation only and is limited to registered Healthcare Professionals. The company seeks no commitment from external stakeholders to take any action as a result of the invitation or related support. In accordance with the Code of Conduct for the prescription medicines industry in Australia, any costs (for example travel or meals) incurred by a partner/spouse, guest or family member travelling with a healthcare professional must not be paid for or subsidised by the company.

PRIVACY STATEMENT: Your personal information ("Information") will be collected and used by AstraZeneca Pty Ltd ("AstraZeneca") for the purpose of administration of this meeting, for follow-up purposes and for any other purpose described in AstraZeneca's Privacy Policy (see below for link).

AstraZeneca may disclose your Information to third parties such as our related entities or service providers (including IT support/service providers), some of which may be located overseas including in the US, European Union and Asia Pacific. Please refer to our [Privacy Policy](https://www.astrazeneca.com.au/privacy-policy.html) (<https://www.astrazeneca.com.au/privacy-policy.html>) for more information about how your Information is handled and how you may seek to access or correct your Information, or submit a privacy complaint.

BREZTRI AEROSPHERE® is a registered trademark of the AstraZeneca group of companies. AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via <https://contactazmedical.astrazeneca.com> Or email Medical Information enquiries to medinfo.australia@astrazeneca.com.